{"nctId":"NCT03772665","briefTitle":"Safety and Efficacy of Emixustat in Stargardt Disease","startDateStruct":{"date":"2019-01-07","type":"ACTUAL"},"conditions":["Stargardt Disease"],"count":194,"armGroups":[{"label":"Emixustat","type":"EXPERIMENTAL","interventionNames":["Drug: Emixustat"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Emixustat","otherNames":["emixustat hydrochloride"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* A clinical diagnosis of macular atrophy secondary to Stargardt disease (STGD)\n* Macular atrophy measured to fall within a defined size range\n* Two mutations of the ABCA4 gene. If only one mutation, a typical STGD appearance of the retina.\n* Visual acuity in the study eye of at least 20/320\n\nExclusion Criteria:\n\n* Macular atrophy secondary to a disease other than STGD\n* Mutations of genes, other than ABCA4, that are associated with retinal degeneration\n* Surgery in the study eye in the past 3 months\n* Prior participation in a gene therapy or stem cell clinical trial for STGD\n* Recent participation in a clinical trial for STGD evaluating a complement inhibitor or vitamin A derivative\n* Use of certain medications in the past 4 weeks that might interfere with emixustat\n* An abnormal electrocardiogram (ECG)\n* Certain abnormalities on laboratory blood testing\n* Female subjects who are pregnant or nursing","healthyVolunteers":false,"sex":"ALL","minimumAge":"16 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Rate of Change in Total Area of Macular Atrophy, as Measured by Fundus Autofluorescence (FAF)","description":"Mean rate of change in total area of macular atrophy, as measured by fundus autofluorescence (FAF)","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.280","spread":"0.0783"},{"groupId":"OG001","value":"1.309","spread":"0.1002"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":9,"n":127},"commonTop":["Visual acuity reduced"]}}}